J Korean Med Sci.  2006 Oct;21(5):871-876. 10.3346/jkms.2006.21.5.871.

Expression of Cyclooxygenase-2, p53 and Ki-67 in Gastric Cancer

• Joo YE
• Chung IJ
• Park YK
• Koh YS
• Lee JH
• Park CH
• Lee WS
• Kim HS
• Choi SK
• Rew JS
• Park CS
• Kim SJ

• KMID: 1781908
• DOI: http://doi.org/10.3346/jkms.2006.21.5.871

Abstract

It has been reported that p53 mutation may contribute to upregulate cyclooxygenase (COX)-2 expression that is observed in malignant tissues. These molecules are involved in carcinogenesis by affecting tumor cell proliferation. The aim of this study was to examine the relationship between COX-2 or p53 expression and clinico-pathological characteristics including tumor cell proliferation in gastric cancer. COX-2 and p53 expressions were investigated with immunostaining, in tissue specimens obtained from 119 patients who underwent surgery for gastric cancer. The Ki-67 labeling index (LI) was counted by Ki-67 immunostaining. COX-2 and p53 expressions correlated significantly with depth of tumor invasion. However, there was no association between COX-2 or p53 expression and survival. p53 expression did not correlate with COX-2 expression. There was no significant difference in various clinicopathological variables between Ki-67 LI subgroups. The mean Ki-67 LI value of COX-2 positive tumors was significantly higher than that of negative tumors. The mean Ki-67 LI value of p53 positive tumors was not significantly higher than that of negative tumors. The mean Ki-67 LI value of both COX-2 and p53 positive tumors was significantly higher than that of both negative tumors. These results imply that COX-2 expression is associated with tumor cell proliferation of gastric cancer.

Keyword

Cyclooxygenase 2; Tumor Suppressor Protein p53; Cell Proliferation; Stomach Neoplasms; Immu-nohistochemistry

MeSH Terms

Tumor Suppressor Protein p53/*analysis
Stomach Neoplasms/*chemistry/mortality/pathology
Prognosis
Middle Aged
Male
Ki-67 Antigen/*analysis
Immunohistochemistry
Humans
Female
Cyclooxygenase 2/*analysis
Aged
Adult

Figure

• 

  Fig. 1 Immunoreactivity of COX-2 in gastric cancer tissues. COX-2 immunoreactivity is predominantly detected in the cytoplasm of cancer cells (×200).

• 

  Fig. 2 Kaplan-Meier survival curve correlating disease specific survival with positive (solid line) or negative (dotted line) expression of COX-2 (A), p53 (B), and high (solid line) or low (dotted line) Ki-67 LI (C).

Reference

1. DuBois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE. Cyclooxygenase in biology and disease. FASEB J. 1998. 12:1063–1073.

2. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998. 38:97–120.

3. Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem. 1993. 268:9049–9054.

4. Xie W, Herschman HR. Transcriptional regulation of prostaglandin synthase 2 gene expression by platelet-derived growth factor and serum. J Biol Chem. 1996. 271:31742–31748.

5. Sheng H, Williams CS, Shao J, Liang P, DuBois RN, Beauchamp RD. Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway. J Biol Chem. 1998. 273:22120–22127.

6. Joo YE, Kim HS, Min SW, Lee WS, Park CH, Park CS, Choi SK, Rew JS, Kim SJ. Expression of cyclooxygenase-2 protein in colorectal carcinomas. Int J Gastrointest Cancer. 2002. 31:147–154.

7. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 1999. 59:198–204.

8. Joo YE, Oh WT, Rew JS, Park CS, Choi SK, Kim SJ. Cyclooxygenase-2 expression is associated with well-differentiated and intestinal-type pathways in gastric carcinogenesis. Digestion. 2002. 66:222–229.

9. Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB, Subbaramaiah K. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol. 2001. 2:544–551.

10. Thun MJ. NSAID use and decreased risk of gastrointestinal cancers. Gastroenterol Clin North Am. 1996. 25:333–348.

11. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995. 83:493–501.

12. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA. 1997. 94:3336–3340.

13. Kambayashi T, Alexander HR, Fong M, Strassmann G. Potential involvement of IL-10 in suppressing tumour-associated macrophages. Colon-26-derived prostaglandin E2 inhibits TNF-alpha release via a mechanism involving IL-10. J Immunol. 1995. 154:3383–3390.

14. Cianchi F, Cortesini C, Bechi P, Fantappie O, Messerini L, Vannacci A, Sardi I, Baroni G, Boddi V, Mazzanti R, Masini E. Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology. 2001. 121:1339–1347.

15. Joo YE, Rew JS, Seo YH, Choi SK, Kim YJ, Park CS, Kim SJ. Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer. J Clin Gastroenterol. 2003. 37:28–33.

16. Weidner N, Moore DH 2nd, Vartanian R. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB1 antibody. Hum Pathol. 1994. 25:337–342.

17. Chan AO, Luk JM, Hui WM, Lam SK. Molecular biology of gastric carcinoma: From laboratory to bedside. J Gastroenterol Hepatol. 1999. 14:1150–1160.

18. Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A, Dannenberg AJ. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem. 1999. 274:10911–10915.

19. Leung WK, To KF, Ng YP, Lee TL, Lau JY, Chan FK, Ng EK, Chung SC, Sung JJ. Association between cyclooxygenase-2 overexpression and missense p53 mutations in gastric cancer. Br J Cancer. 2001. 84:335–339.

20. Fleming ID. American Joint Committee on Cancer Classification (AJCC). AJCC cancer staging manual. 1997. Philadelphia: Lippincott-Raven;71–76.

21. Reed JA, Manahan LJ, Park CS, Brigati DJ. Complete one-hour immunocytochemistry based on capillary action. Biotechniques. 1992. 13:434–443.

22. Yamagishi M, Noda M, Tatsumi Y, Mukaisho K, Mitsufuji S, Sugihara H, Okanoue T, Hattori T. Correlation between cyclooxygenase-2, proliferative activity, and mucin phenotype in human advanced gastric cancer. J Gastroenterol. 2004. 39:1143–1149.

23. Sawaoka H, Kawano S, Tsuji S, Tsujii M, Murata H, Hori M. Effects of NSAIDs on proliferation of gastric cancer cells in vitro: possible implication of cyclooxygenase-2 in cancer development. J Clin Gastroenterol. 1998. 27:Suppl 1. 47–52.

24. Mack DH, Vartikar J, Pipas JM, Laimins LA. Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature. 1993. 363:281–283.

25. Prives C, Hall PA. The p53 pathway. J Pathol. 1999. 187:112–126.

26. Chen G, Burger MM. p150 overexpression in gastric carcinoma: the association with p53, apoptosis and cell proliferation. Int J Cancer. 2004. 112:393–398.

27. Ishii HH, Gobe GC, Pan W, Yoneyama J, Ebihara Y. Apoptosis and cell proliferation in the development of gastric carcinomas: associations with c-myc and p53 protein expression. J Gastroenterol Hepatol. 2002. 17:966–972.

28. Murata H, Kawano S, Tsuji S, Tsuji M, Sawaoka H, Kimura Y, Shiozaki H, Hori M. Cyclooxygenase 2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol. 1999. 94:451–455.

29. Lim HY, Joo HJ, Choi JH, Yi JW, Yang MS, Cho DY, Kim HS, Nam DK, Lee KB, Kim HC. Increased expression of cyclooxygenase 2 protein in human gastric carcinoma. Clin Cancer Res. 2000. 6:519–525.

30. Igarashi N, Takahashi M, Ohkubo H, Omata K, Iida R, Fujimoto S. Predictive value of Ki-67, p53 protein, and DNA content in the diagnosis of gastric carcinoma. Cancer. 1999. 86:1449–1454.

31. Kakeji Y, Korenaga D, Tsujitani S, Baba H, Anai H, Maehara Y, Sugimachi K. Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes. Br J Cancer. 1993. 67:589–593.

32. Liu XP, Tsushimi K, Tsushimi M, Kawauchi S, Oga A, Furuya T, Sasaki K. Expression of p21 (WAF1/CIP1) and p53 proteins in gastric carcinoma: its relationships with cell proliferation activity and prognosis. Cancer Lett. 2001. 170:183–189.

33. Kanai T, Konno H, Maruyama K, Baba M, Tanaka T, Maruo Y, Nishino N, Nakamura S, Baba S, Sugimura H. p53 overexpression and proliferative activity do not correlate with lymph node metastasis in early gastric cancer. Eur Surg Res. 1997. 29:35–41.